The Therapeutic Effect of Ge-Gen Decoction on a Rat Model of Primary Dysmenorrhea: Label-Free Quantitative Proteomics and Bioinformatic Analyses

Ge-Gen decoction (GGD) is widely used for the treatment of primary dysmenorrhea (PD) in China. However, the mechanisms that underlie this effect are unclear. We investigated the protective mechanism of GGD in a rat model of PD using label-free quantitative proteomics. The model was established by th...

Full description

Bibliographic Details
Main Authors: Yazhen Xie, Jianqiang Qian, Qibin Lu
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2020/5840967
id doaj-a4c895b7cc7f45519ad140bbe43656be
record_format Article
spelling doaj-a4c895b7cc7f45519ad140bbe43656be2020-12-14T09:46:33ZengHindawi LimitedBioMed Research International2314-61332314-61412020-01-01202010.1155/2020/58409675840967The Therapeutic Effect of Ge-Gen Decoction on a Rat Model of Primary Dysmenorrhea: Label-Free Quantitative Proteomics and Bioinformatic AnalysesYazhen Xie0Jianqiang Qian1Qibin Lu2Taicang Traditional Chinese Medicine Hospital, Affiliated to Nanjing University of Chinese Medicine, Taicang 215400, ChinaTaicang Traditional Chinese Medicine Hospital, Affiliated to Nanjing University of Chinese Medicine, Taicang 215400, ChinaDepartment of Gynaecology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, ChinaGe-Gen decoction (GGD) is widely used for the treatment of primary dysmenorrhea (PD) in China. However, the mechanisms that underlie this effect are unclear. We investigated the protective mechanism of GGD in a rat model of PD using label-free quantitative proteomics. The model was established by the administration of estradiol benzoate and oxytocin. Thirty rats were divided into three groups (ten rats/group): a control group (normal rats), a model group (PD rats), and a treatment group (PD rats treated with GGD). The serum levels of prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) were measured by ELISA. Nanohigh-performance liquid chromatography-tandem mass spectrometry (nano-HPLC-MS/MS) was used to identify differentially expressed proteins (DEPs), and bioinformatics was used to investigate the protein function. Proteomic data were validated by western blot analysis. Oxytocin-induced writhing responses and abnormal serum levels of PGE2 and PGF2α were reversed following the administration of GGD. A total of 379 DEPs were identified; 276 were identified between the control group and the model group, 144 were identified between the model group and the treatment group, and 41 were identified as DEPs that were common to all groups. Bioinformatics revealed that the DEPs between the control group and the model group were mainly associated with cellular component biogenesis and binding processes. The DEPs between the model group and the treatment group were mainly involved in the protein binding and metabolic process. The expression levels of HSP90AB1 and the phosphorylation levels of ERK, JNK, and P-p38 in the uteri of rats in the three groups were consistent with the proteomic findings; MAP kinases (ERK, JNK, and p38) are known to be involved in the production of inflammatory cytokines and oxytocin signaling while HSP90AB1 is known to be associated with estrogen signaling. Collectively, these data indicate that GGD may exert its protective function on PD by regulating the inflammatory response and signaling pathways associated with oxytocin and estrogen.http://dx.doi.org/10.1155/2020/5840967
collection DOAJ
language English
format Article
sources DOAJ
author Yazhen Xie
Jianqiang Qian
Qibin Lu
spellingShingle Yazhen Xie
Jianqiang Qian
Qibin Lu
The Therapeutic Effect of Ge-Gen Decoction on a Rat Model of Primary Dysmenorrhea: Label-Free Quantitative Proteomics and Bioinformatic Analyses
BioMed Research International
author_facet Yazhen Xie
Jianqiang Qian
Qibin Lu
author_sort Yazhen Xie
title The Therapeutic Effect of Ge-Gen Decoction on a Rat Model of Primary Dysmenorrhea: Label-Free Quantitative Proteomics and Bioinformatic Analyses
title_short The Therapeutic Effect of Ge-Gen Decoction on a Rat Model of Primary Dysmenorrhea: Label-Free Quantitative Proteomics and Bioinformatic Analyses
title_full The Therapeutic Effect of Ge-Gen Decoction on a Rat Model of Primary Dysmenorrhea: Label-Free Quantitative Proteomics and Bioinformatic Analyses
title_fullStr The Therapeutic Effect of Ge-Gen Decoction on a Rat Model of Primary Dysmenorrhea: Label-Free Quantitative Proteomics and Bioinformatic Analyses
title_full_unstemmed The Therapeutic Effect of Ge-Gen Decoction on a Rat Model of Primary Dysmenorrhea: Label-Free Quantitative Proteomics and Bioinformatic Analyses
title_sort therapeutic effect of ge-gen decoction on a rat model of primary dysmenorrhea: label-free quantitative proteomics and bioinformatic analyses
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2020-01-01
description Ge-Gen decoction (GGD) is widely used for the treatment of primary dysmenorrhea (PD) in China. However, the mechanisms that underlie this effect are unclear. We investigated the protective mechanism of GGD in a rat model of PD using label-free quantitative proteomics. The model was established by the administration of estradiol benzoate and oxytocin. Thirty rats were divided into three groups (ten rats/group): a control group (normal rats), a model group (PD rats), and a treatment group (PD rats treated with GGD). The serum levels of prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) were measured by ELISA. Nanohigh-performance liquid chromatography-tandem mass spectrometry (nano-HPLC-MS/MS) was used to identify differentially expressed proteins (DEPs), and bioinformatics was used to investigate the protein function. Proteomic data were validated by western blot analysis. Oxytocin-induced writhing responses and abnormal serum levels of PGE2 and PGF2α were reversed following the administration of GGD. A total of 379 DEPs were identified; 276 were identified between the control group and the model group, 144 were identified between the model group and the treatment group, and 41 were identified as DEPs that were common to all groups. Bioinformatics revealed that the DEPs between the control group and the model group were mainly associated with cellular component biogenesis and binding processes. The DEPs between the model group and the treatment group were mainly involved in the protein binding and metabolic process. The expression levels of HSP90AB1 and the phosphorylation levels of ERK, JNK, and P-p38 in the uteri of rats in the three groups were consistent with the proteomic findings; MAP kinases (ERK, JNK, and p38) are known to be involved in the production of inflammatory cytokines and oxytocin signaling while HSP90AB1 is known to be associated with estrogen signaling. Collectively, these data indicate that GGD may exert its protective function on PD by regulating the inflammatory response and signaling pathways associated with oxytocin and estrogen.
url http://dx.doi.org/10.1155/2020/5840967
work_keys_str_mv AT yazhenxie thetherapeuticeffectofgegendecoctiononaratmodelofprimarydysmenorrhealabelfreequantitativeproteomicsandbioinformaticanalyses
AT jianqiangqian thetherapeuticeffectofgegendecoctiononaratmodelofprimarydysmenorrhealabelfreequantitativeproteomicsandbioinformaticanalyses
AT qibinlu thetherapeuticeffectofgegendecoctiononaratmodelofprimarydysmenorrhealabelfreequantitativeproteomicsandbioinformaticanalyses
AT yazhenxie therapeuticeffectofgegendecoctiononaratmodelofprimarydysmenorrhealabelfreequantitativeproteomicsandbioinformaticanalyses
AT jianqiangqian therapeuticeffectofgegendecoctiononaratmodelofprimarydysmenorrhealabelfreequantitativeproteomicsandbioinformaticanalyses
AT qibinlu therapeuticeffectofgegendecoctiononaratmodelofprimarydysmenorrhealabelfreequantitativeproteomicsandbioinformaticanalyses
_version_ 1714998447426240512